MicroRNAs (miRNAs) are non-coding RNA transcripts that regulate physiological processes by targeting proteins directly. Their involvement in research has been robust, and evidence of their regulative functions has granted them the title: master regulators of the human genome. In cancer, they have been considered important therapeutic agents, due to the fact that their aberrant expression contributes to disease development, progression, metastasis, therapeutic response and patient overall survival. This has endeavored fields of biomedical sciences to invest in developing and exploiting miRNA-based therapeutics thoroughly. Herein we highlight relevant ongoing/open clinical trials involving miRNAs and cancer.
The pervasive role of microRNAs (miRNAs) in cancer pathobiology drives the introduction of new drug development approaches such as miRNA inhibition. In order to advance miRNA-therapeutics, meticulous screening strategies addressing specific tumor targets are needed. Small molecule inhibitors represent an attractive goal for these strategies. In this study, we devised a strategy to screen for small molecule inhibitors that specifically inhibit, directly or indirectly, miR-10b (SMIRs) which is overexpressed in metastatic tumors. We found that the multi-tyrosine kinase inhibitor linifanib could significantly inhibit miR-10b and reverse its oncogenic function in breast cancer and liver cancer both in vitro and in vivo. In addition, we showed that the efficacy of linifanib to inhibit tyrosine kinases was reduced by high miR-10b levels. When the level of miR-10b is high, it can “hijack” the linifanib and reduce its kinase inhibitory effects in cancer resulting in reduced anti-tumor efficacy. In conclusion, our study describes an effective strategy to screen for small molecule inhibitors of miRNAs. We further propose that miR-10b expression levels, due to the newly described “hijacking” effect, may be used as a biomarker to select patients for linifanib treatment.
This work is the continuation of a study focused on establishing relations between surface thermodynamic properties and in vitro release mechanisms using a model drug (ampicillin trihydrate), besides analyzing the granulometric properties of new polymeric materials and thus establishing the potential to be used in the pharmaceutical field as modified delivery excipients. To do this, we used copolymeric materials derived from maleic anhydride with decreasing polarity corresponding to poly(isobutylene-alt-maleic acid) (hydrophilic), sodium salt of poly(maleic acid-alt-octadecene) (amphiphilic), poly(maleic anhydride-alt-octadecene) (hydrophobic) and the reference polymer hydroxyl-propyl-methyl-cellulose (HPMC). Each material alone and in blends underwent spectroscopic characterization by FTIR, thermal characterization by DSC and granulometric characterization using flow and compaction tests. Each tablet was prepared at different polymer ratios of 0%, 10%, 20%, 30% and 40%, and the surface properties were determined, including the roughness by micro-visualization, contact angle and water absorption rate by the sessile drop method and obtaining Wadh and surface free energy (SFE) using the semi-empirical models of Young–Dupré and Owens-Wendt-Rabel-Käelbe (OWRK), respectively. Dissolution profiles were determined simulating physiological conditions in vitro, where the kinetic models of order-zero, order-one, Higuchi and Korsmeyer–Peppas were evaluated. The results showed a strong relationship between the proportion and nature of the polymer to the surface thermodynamic properties and kinetic release mechanism.
The host immune response can be evaded by tumor cells, e.g., through upregulation of the PD-L1/PD-1 immune checkpoint, and - paradoxically - even hijacked to promote cancer progression. Here we showed that B lymphocytes, which can produce anti-tumoral antibodies/autoantibodies in breast cancer (BCa), played an important role in promoting murine BCa development, as B cell-deficient μMT mice displayed virtually abrogated tumor growth from transplanted syngeneic ERα+ breast adenocarcinoma cells, concomitant with significantly reduced PD-L1 expression and much increased cell death in residual tumors. In BCa that grew in wildtype mice and in tumor-associated ectopic lymph nodes, B cells were the major source of IL-27, which is the IL-27p28/EBI3 heterodimer and a pleotropic cytokine with both pro- and anti-inflammatory functions. Deficiency in IL-27 expression specifically in B cells also significantly reduced the BCa growth, indicating that the effect of B cells in BCa development was mainly through IL-27 production. This was effectively induced in B cells primed by TLR ligands, including those that would be released during uncontrolled cell death in the tumor microenvironment, and stimulated by CD154 and IL-21, as likely expressed by activated tumor-infiltrating CD4+ T cells. IL-27 in turn triggered JAK-dependent STAT1 and STAT3 phosphorylation in BCa cells, enhanced PD-L1 gene expression and promoted growth of these cells. In addition, among the 2040 genes compiled by the Ingenuity Pathway Analysis as involved in BCa tumorigenesis, those encoding PD-L1, IFN-γ and Hif-1α (cytokine and transcription factor known to induce PD-L1, respectively), IDO-1, chemokine receptor CXCR3 and its ligand CXCL10 were specifically upregulated in B cells by IL-27, which also induced an overall gene signature similar to what induced by IFN-γ, reflecting the activation of STAT1 and STAT3 by both cytokines. In humans, the two genes encoding IL-27 receptor subunits were highly expressed in the breast tissue, at levels comparable to those in lymphoid organs. As shown by The Cancer Genome Atlas (TCGA) and The Kaplan Meier Plotter datasets, the higher IL27p28 expression was associated with worse survival in BCa patients overall, who displayed increased circulating IL-27 levels as compared to healthy subjects, and in ER+ BCa patients after endocrine therapies. Indeed, IL-27 supported human BCa cell growth in the presence of tamoxifen, suggesting a role of B cell-produced IL-27 in the acquisition of drug resistance by BCa. Thus, TLR-fueled IL-27 induction in B cells reinforces PD-L1 expression in the tumor environment to drive BCa cell-intrinsic growth mechanisms and generation of PD-L1+ B regulatory cells involved in the immune checkpoint, leading to BCa progression and possibly anti-estrogen therapy resistance. Citation Format: Hui Yan, Suryavathi Viswanadhapalli, Daniel Chupp, Maria Fernandez, Shuai Wu, Jingwei Wang, Justin Moroney, Julia Taylor, John Im, Carlos Rivera, Yiliao Luo, Junhao Liu, Gangadhara Sareddy, Paolo Casali, Ratna Vadlamudi, Zhenming Xu. B cell-produced IL-27 up-regulates PD-L1 expression in the tumor microenvironment to promote breast cancer development [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3250.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.